UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy
(Reuters) -UniQure, said on Monday the U.S. health regulator has deemed clinical data for its gene therapy for Huntington's disease as inadequate, sending the Dutch company's U.S.-listed shares plummeting over 68% in premarket trading. The company's shares...
Reuters